Document Detail


Cetuximab: a guide to its use in combination with FOLFIRI in the first-line treatment of metastatic colorectal cancer in the USA.
MedLine Citation:
PMID:  23055389     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Cetuximab (Erbitux(®)) is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR). In the USA, the approval of cetuximab has been recently expanded to include the first-line treatment of patients with KRAS mutation-negative (wild-type), EGFR-expressing, metastatic colorectal cancer (mCRC) when used in combination with FOLFIRI (irinotecan, fluorouracil, leucovorin [folinic acid]). The addition of cetuximab to first-line treatment with FOLFIRI improved progression-free survival, overall survival, and objective response rates relative to treatment with FOLFIRI alone in patients with EGFR-expressing mCRC with KRAS wild-type tumors. Therefore, cetuximab plus FOLFIRI is a useful biomarker-directed option in the first-line treatment of this patient population.
Authors:
Katherine A Lyseng-Williamson
Related Documents :
8423019 - A new aggressive treatment approach to high-grade endometrial cancer of possible benefi...
19471649 - Adjuvant therapy in high-risk early endometrial carcinoma: a retrospective analysis of ...
20660059 - Treatment for advanced and recurrent endometrial carcinoma: combined modalities.
10534159 - Clinical relevance of the histological classification of sinonasal intestinal-type aden...
17547889 - Stage iii endometrial cancer: preoperative predictability, prognostic factors, and trea...
1659199 - Postpartum vaginal atrophy.
7888829 - Current status and future perspectives in the treatment of low-grade non-hodgkin's lymp...
9283919 - Long-term survival in a case of high-risk type igd myeloma; a possibility of effectiven...
10493029 - Endobronchial metastatic disease.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Molecular diagnosis & therapy     Volume:  16     ISSN:  1179-2000     ISO Abbreviation:  Mol Diagn Ther     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-19     Completed Date:  2013-03-28     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  101264260     Medline TA:  Mol Diagn Ther     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  317-22     Citation Subset:  IM    
Affiliation:
Adis, Auckland, New Zealand. mdt@adis.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Camptothecin / analogs & derivatives,  therapeutic use
Colorectal Neoplasms / drug therapy*,  pathology
Disease-Free Survival
Fluorouracil / therapeutic use
Gene Expression Regulation, Neoplastic
Guidelines as Topic
Humans
Leucovorin / therapeutic use
Mutation
Neoplasm Metastasis
Proto-Oncogene Proteins / genetics,  metabolism
Receptor, Epidermal Growth Factor / antagonists & inhibitors,  genetics,  metabolism
ras Proteins / genetics,  metabolism
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/KRAS protein, human; 0/Proto-Oncogene Proteins; 51-21-8/Fluorouracil; 58-05-9/Leucovorin; 7689-03-4/Camptothecin; EC 2.7.10.1/Receptor, Epidermal Growth Factor; EC 3.6.5.2/ras Proteins; PQX0D8J21J/cetuximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Significance of plasma osteopontin levels in patients with bladder urothelial carcinomas.
Next Document:  Large enhancement of oscillating chemiluminescence with [Ru(bpy)(3) ](2+) -catalyzed Belousov-Zhabot...